Abstract |
The Lewis lung carcinoma implanted subcutaneously in the hind leg of a C57BL mouse metastasizes avidly to the lungs of the host. This tumour model system thus allows assessment of both primary and metastatic disease to treatment. Lonidamine (50 mg/kg) administered once or twice daily produced approximately additive tumour growth delay with whole-body hyperthermia (60 min to 42 degrees C and 60 min at 42 degrees C). The addition of lonidamine to treatment with cisplatin (10 mg/kg) and whole-body hyperthermia continued to produce increased tumour growth delay of up to 14.7 days compared with 10.8 days for cisplatin/whole-body hyperthermia. The response of the metastatic disease paralleled that of the primary tumour with a reduction in the number and percent of large metastases (> 3 mm) on day 20 post-tumour implantation. The addition of local fractionated radiation therapy (3 Gy x 5) to the primary tumour produced a very effective treatment regimen resulting in 37.5 days of tumour growth delay along with twice daily lonidamine/ cisplatin whole-body hyperthermia. With this treatment regimen there was also a reduction to 50% of control of the number of lung metastases as well as the percent of large metastases on day 20. Further investigation of these treatment combinations is warranted.
|
Authors | B A Teicher, S A Holden, G Ara, K Menon |
Journal | International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
(Int J Hyperthermia)
1995 Sep-Oct
Vol. 11
Issue 5
Pg. 637-45
ISSN: 0265-6736 [Print] England |
PMID | 7594815
(Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- Antineoplastic Agents
- Indazoles
- Cisplatin
- lonidamine
|
Topics |
- Animals
- Antineoplastic Agents
(administration & dosage, therapeutic use)
- Chemotherapy, Adjuvant
- Cisplatin
(administration & dosage, therapeutic use)
- Combined Modality Therapy
- Evaluation Studies as Topic
- Hyperthermia, Induced
- Indazoles
(administration & dosage, therapeutic use)
- Lung Neoplasms
(drug therapy, radiotherapy, secondary, therapy)
- Male
- Mice
- Mice, Inbred C57BL
- Radiotherapy, Adjuvant
|